2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights

Mostafa M. Elbadawi, Wagdy M. Eldehna, Amer Ali Abd El‐Hafeez, Warda R. Somaa, Amgad Albohy, Sara T. Al‐Rashood, Keli Agama, Eslam B. Elkaeed, Pradipta Ghosh, Yves Pommier,

Journal of Enzyme Inhibition and Medicinal Chemistry · 2021 · 41 citations · 51 references

DOIFull text

Open access

Concepts

Abstract

s = 22.68, 14.25, 18.36, 17.36, and 15.36 nM, respectively). Finally, molecular modelling was employed to justify the promising EGFR/FAK inhibition. The study outcomes afforded the first reported quinolines with potent EGFR/FAK dual inhibition.

References

51